Skip to main content
Back
Watch Compare

Lineage Cell Therapeutics, Inc.

Data quality: 100%
LCTX
NYSE Manufacturing Chemicals
$1.63
▲ $0.04 (2.52%)
6 months return
—
Momentum
Neutral
5Y revenue growth
35.32%

Growth

Revenue Growth (5Y)
35.32%
Above sector avg (1.72%)
Revenue (1Y)53.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-180.43%
Below sector avg (-54.47%)
ROIC-36.09%
Net Margin-436.47%
Op. Margin-251.57%

Safety

Debt / Equity
N/A
Current Ratio4.50
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-5.80 | -19.10
Below sector avg (-1.50)
P/B Ratio16.73
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 35.32% annually over 5 years — strong growth
Negative free cash flow of -19.44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 17.92%
Capital efficient — spends only 3.59% of revenue on capex

Price History

Financial Trends

Analyst Price Target

6 analysts
Buy
+176.1%
upside to target
Current
$1.63
Consensus Target
$4.50
$3.00
Low
$9.00
High
Forecast
Forward P/E
-19.10
Forward EPS
-$0.08
Est. Revenue
21.36 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.02 · Rev Est: 4.02 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.02 -$0.13 -$0.13 $0.00 — —
Estimate -$0.03 -$0.03 -$0.03 -$0.04 -$0.02 $0.00
Surprise +28.57% -358.88% -358.88% +100.00% — —

Growth

Rev 5Y: 35.32% · Earnings 1Y: N/A
Revenue Growth (1Y) 53.24% Revenue Growth (3Y) 27.56%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 35.32% Earnings Growth (5Y) N/A

Profitability

ROE: -180.43% · Net Margin: -436.47%
Revenue (TTM) 14.56 M Net Income (TTM) -63.53 M
ROE -180.43% ROA -70.42%
Gross Margin N/A Operating Margin -251.57%
Net Margin -436.47% Free Cash Flow (TTM) -19.44 M
ROIC -36.09% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 4.50
Debt / Equity N/A Current Ratio 4.50
Interest Coverage N/A Asset Turnover 0.16
Working Capital 32.88 M Tangible Book Value -20.33 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -5.80 · EV/EBITDA: N/A
P/E Ratio -5.80 Forward P/E -19.10
P/B Ratio 16.73 P/S Ratio 25.33
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 17.26 Fwd Earnings Yield N/A
FCF Yield -5.27%
Market Cap 368.65 M Enterprise Value 328.19 M

Per Share

EPS: -0.28 · FCF/Share: -0.08
EPS (Diluted TTM) -0.28 Revenue / Share 0.06
FCF / Share -0.08 OCF / Share -0.08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 30.60% · CapEx/Rev: 3.59%
CapEx / Revenue 3.59% FCF Conversion 30.60%
SBC-Adj. FCF -24.43 M Growth Momentum 17.92

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.56 M 9.50 M 8.95 M 14.70 M 4.34 M
Net Income -63.53 M -18.61 M -21.49 M -26.27 M -43.02 M
EPS (Diluted) -0.28 -0.09 -0.12 — —
Gross Profit — — 8.27 M 13.98 M 2.92 M
Operating Income -36.62 M -21.48 M -24.73 M -22.52 M -49.21 M
EBITDA — — — — —
R&D Expenses 17.73 M 12.47 M 15.71 M 13.99 M 33.91 M
SG&A Expenses — — — — —
D&A 699,000.0 587,000.0 562,000.0 582,000.0 663,000.0
Interest Expense — — — 829,000.0 2,000.0
Income Tax -5.28 M 0.0 -1.80 M 541,000.0 -1.24 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112.58 M 113.22 M 101.02 M 123.66 M 174.55 M
Total Liabilities 69.24 M 36.21 M 39.00 M 51.73 M 83.65 M
Shareholders' Equity 44.55 M 78.38 M 63.42 M 73.34 M 92.22 M
Total Debt — — — — —
Cash & Equivalents 40.79 M 45.79 M 35.44 M 11.36 M 55.74 M
Current Assets 59.16 M 51.00 M 38.44 M 60.00 M 111.55 M
Current Liabilities 11.37 M 13.98 M 17.96 M 18.98 M 47.12 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -5.8 -1.5
P/B 16.7 1.6
ROE % -180.4 -54.5
Net Margin % -436.5 -41.5
Rev Growth 5Y % 35.3 1.7
D/E — 0.3

ETFs Holding This Stock
BRSIX BRSIX
0.08% weight